Skip to search formSkip to main contentSkip to account menu

SAR 3419

Known as: Anti-CD19-DM4 Immunoconjugate SAR3419, SAR-3419, SAR3419 
An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Antibodies, Monoclonal, HumanizedMaytansine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the… 
2014
2014
Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL…
8506 Background: CoR is an anti-CD19 antibody maytansinoid conjugate. CD19 is expressed in the majority of B cell lymphomas… 
Review
2013
Review
2013
Review of Antibody-Drug Conjugates, Methods in Molecular Biology series
Antibody-drug conjugates (ADCs) represent an exciting and promising therapeutic approach for the treatment of cancers. The US… 
2013
2013
Phase II Study Of Anti-CD19 Antibody Drug Conjugate (SAR3419) In Combination With Rituximab: Clinical Activity and Safety In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma…
Background SAR3419 is a humanized anti-CD19 antibody conjugated to maytansin DM4, a potent cytotoxic agent. SAR3419 targets CD19… 
2012
2012
Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell…
8057 Background: The recommended dose (RD) of SAR3419 administered intravenously every 3 weeks (q3w) for 6 cycles is 160 mg/m2… 
2012
2012
Antibody-drug conjugate technology development for hematologic disorders.
Antibody-drug conjugates (ADCs) combine cytotoxic chemotherapy and antibody specificity. There are 4 components of ADC technology… 
2011
2011
Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).
8017 Background: SAR3419 (huB4-DM4) is an antibody-drug conjugate composed of a humanized IgG1 monoclonal antibody, huB4, which… 
Review
2011
Review
2011
Benlysta makes history
volume 29 number 4 april 2011 nature biotechnology Another cancer-killing conjugate is ImmunoGen’s IMGN901 (lorvotuzumab… 
Review
2011
Review
2011
Open access consortium
volume 29 number 4 april 2011 nature biotechnology Another cancer-killing conjugate is ImmunoGen’s IMGN901 (lorvotuzumab… 
2008
2008
192 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the anti-CD19-DM4 conjugated antibody SAR3419
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)